Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 24-Sep-24 4:01 PM View:  | Costa Carlos Chief People Officer | Foghorn Therapeutics Inc. (FHTX) | 23-Sep-24 | Planned Option Sale | 857 | $10.17 | $8,715.69 | (100%) 0.86K to 0 | |
| 24-Sep-24 4:01 PM View: | Costa Carlos Chief People Officer | Foghorn Therapeutics Inc. (FHTX) | 23-Sep-24 | Option Exercise | 857 | $3.72 | $3,188.04 | 100% 0 to 0.86K | |
| 24-Sep-24 4:01 PM View: | Costa Carlos Chief People Officer | Foghorn Therapeutics Inc. (FHTX) | 20-Sep-24 | Option Exercise | 35,756 | $3.72 | $133,012.00 | 100% 0 to 35.76K | |
| 24-Sep-24 4:01 PM View: | Costa Carlos Chief People Officer | Foghorn Therapeutics Inc. (FHTX) | 20-Sep-24 | Planned Option Sale | 35,756 | $10.04 | $358,990.00 | (100%) 35.76K to 0 | |
| 20-Sep-24 4:00 PM View: | Costa Carlos Chief People Officer | Foghorn Therapeutics Inc. (FHTX) | 18-Sep-24 | Option Exercise | 11,574 | $3.72 | $43,055.30 | 100% 0 to 11.57K | |
| 20-Sep-24 4:00 PM View: | Costa Carlos Chief People Officer | Foghorn Therapeutics Inc. (FHTX) | 18-Sep-24 | Planned Option Sale | 11,574 | $10.05 | $116,319.00 | (100%) 11.57K to 0 | |
| 18-Sep-24 4:01 PM View: | Costa Carlos Chief People Officer | Foghorn Therapeutics Inc. (FHTX) | 17-Sep-24 | Planned Option Sale | 10,272 | $10.04 | $103,131.00 | (100%) 10.27K to 0 | |
| 18-Sep-24 4:01 PM View: | Costa Carlos Chief People Officer | Foghorn Therapeutics Inc. (FHTX) | 17-Sep-24 | Option Exercise | 10,272 | $3.72 | $38,211.80 | 100% 0 to 10.27K | |
| 18-Sep-24 4:01 PM View: | Costa Carlos Chief People Officer | Foghorn Therapeutics Inc. (FHTX) | 16-Sep-24 | Option Exercise | 400 | $3.72 | $1,488.00 | 100% 0 to 0.4K | |
| 18-Sep-24 4:01 PM View: | Costa Carlos Chief People Officer | Foghorn Therapeutics Inc. (FHTX) | 16-Sep-24 | Planned Option Sale | 400 | $10.00 | $4,000.00 | (100%) 0.4K to 0 | |
| 11-Sep-24 4:00 PM View: | Bellon Steven F. Chief Scientific Officer | Foghorn Therapeutics Inc. (FHTX) | 09-Sep-24 | Sale (Planned) | 20,000 | $9.50 | $190,000.00 | (16%) 121.96K to 101.96K | |
| 12-Mar-24 4:19 PM View: | Cavalie Fanny Chief Strategy/Bus Ops Officer | Foghorn Therapeutics Inc. (FHTX) | 11-Mar-24 | Sale | 11,000 | $6.56 | $72,133.60 | (13%) 86.99K to 75.99K | |
| 18-Aug-23 4:03 PM View: | Gottschalk Adrian Chief Executive Officer Director | Foghorn Therapeutics Inc. (FHTX) | 17-Aug-23 | Gift | 63,000 | -- | -- | (11%) 574.7K to 511.7K | |
| 18-Aug-23 4:03 PM View: | Gottschalk Adrian Chief Executive Officer Director | Foghorn Therapeutics Inc. (FHTX) | 17-Aug-23 | Gift | 63,000 | -- | -- | 12% 511.7K to 574.7K | |
| 18-Aug-23 4:03 PM View: | Agresta Samuel Chief Medical Officer | Foghorn Therapeutics Inc. (FHTX) | 16-Aug-23 | Option Exercise | 311,297 | $3.72 | $1,158,020.00 | 100% 0 to 311.3K | |
| 18-Aug-23 4:03 PM View: | Agresta Samuel Chief Medical Officer | Foghorn Therapeutics Inc. (FHTX) | 16-Aug-23 | Option Sale | 311,297 | $8.25 | $2,568,200.00 | (100%) 311.3K to 0 | |
| 31-May-23 9:22 PM View: | Gottschalk Adrian Chief Executive Officer Director | Foghorn Therapeutics Inc. (FHTX) | 26-May-23 | Gift | 300,000 | -- | -- | 67% 448.7K to 748.7K | |
| 31-May-23 9:22 PM View: | Gottschalk Adrian Chief Executive Officer Director | Foghorn Therapeutics Inc. (FHTX) | 26-May-23 | Gift | 300,000 | -- | -- | (40%) 748.7K to 448.7K | |
| 22-Feb-23 4:23 PM View: | Gottschalk Adrian Chief Executive Officer Director | Foghorn Therapeutics Inc. (FHTX) | 17-Feb-23 | Gift | 4,371 | -- | -- | < 1% 1.85M to 1.86M | |
| 22-Feb-23 4:23 PM View: | Gottschalk Adrian Chief Executive Officer Director | Foghorn Therapeutics Inc. (FHTX) | 17-Feb-23 | Disposition (other) | 184,939 | -- | -- | (9%) 2.04M to 1.85M | |
| 22-Feb-23 4:23 PM View: | Gottschalk Adrian Chief Executive Officer Director | Foghorn Therapeutics Inc. (FHTX) | 17-Feb-23 | Gift | 4,371 | -- | -- | (< 1%) 2.04M to 2.04M | |
| 22-Feb-23 4:23 PM View: | Gottschalk Adrian Chief Executive Officer Director | Foghorn Therapeutics Inc. (FHTX) | 17-Feb-23 | Acquisition (other) | 184,939 | -- | -- | 10% 1.86M to 2.04M | |
| 22-Feb-23 4:23 PM View: | Gottschalk Adrian Chief Executive Officer Director | Foghorn Therapeutics Inc. (FHTX) | 25-Oct-22 | Acquisition (other) | 4,371 | -- | -- | < 1% 2.04M to 2.04M | |
| 22-Feb-23 4:23 PM View: | Gottschalk Adrian Chief Executive Officer Director | Foghorn Therapeutics Inc. (FHTX) | 25-Oct-22 | Disposition (other) | 4,371 | -- | -- | (< 1%) 2.04M to 2.04M | |
| 19-Sep-22 4:06 PM View: | Gottschalk Adrian Chief Executive Officer Director | Foghorn Therapeutics Inc. (FHTX) | 16-Sep-22 | Option Exercise | 40,000 | $0.54 | $21,600.00 | 8% 471.7K to 511.7K | |
| 14-Sep-22 8:59 PM View: | Gill Simba Director | Foghorn Therapeutics Inc. (FHTX) | 13-Sep-22 | Gift | 47,939 | -- | -- | (58%) 82.0K to 34.06K | |
| 14-Sep-22 8:59 PM View: | Gill Simba Director | Foghorn Therapeutics Inc. (FHTX) | 12-Sep-22 | Option Exercise | 82,000 | $0.73 | $59,860.00 | 100% 0 to 82.0K | |
| 15-Aug-22 6:15 PM View: | Bellon Steven F. Chief Scientific Officer | Foghorn Therapeutics Inc. (FHTX) | 11-Aug-22 | Option Exercise | 1,858 | $3.72 | $6,911.76 | 1% 170.1K to 171.96K | |
| 27-May-22 10:00 PM View: | Bellon Steven F. Chief Scientific Officer | Foghorn Therapeutics Inc. (FHTX) | 25-May-22 | Option Exercise | 4,392 | $3.26 | $14,320.00 | 3% 165.71K to 170.1K | |
| 22-Feb-23 4:23 PM View: | Gottschalk Adrian Chief Executive Officer Director | Foghorn Therapeutics Inc. (FHTX) | 10-Feb-22 | Gift | 123,479 | -- | -- | (6%) 2.12M to 2.0M | |
| 22-Feb-23 4:23 PM View: | Gottschalk Adrian Chief Executive Officer Director | Foghorn Therapeutics Inc. (FHTX) | 10-Feb-22 | Gift | 123,479 | -- | -- | 6% 2.0M to 2.12M | |
| 16-Dec-21 7:20 PM View: | Kadoch Cigall Director 10% Owner | Foghorn Therapeutics Inc. (FHTX) | 14-Dec-21 | Gift | 333,333 | -- | -- | (8%) 3.96M to 3.62M | |
| 13-Dec-21 8:37 PM View: | Decicco Carl Chief Scientific Officer | Foghorn Therapeutics Inc. (FHTX) | 09-Dec-21 | Option Exercise | 104,310 | $3.72 | $388,033.00 | 40% 258.4K to 362.71K | |
| 23-Aug-21 5:01 PM View: | Gottschalk Adrian Chief Executive Officer Director | Foghorn Therapeutics Inc. (FHTX) | 20-Aug-21 | Option Exercise | 23,000 | $0.54 | $12,420.00 | 5% 448.7K to 471.7K | |
| 11-Aug-21 4:14 PM View: | Reine Allan Chief Financial Officer | Foghorn Therapeutics Inc. (FHTX) | 09-Aug-21 | Option Exercise | 26,892 | $3.72 | $100,038.00 | 100% 26.89K to 53.78K | |
| 29-Oct-20 4:59 PM View: | Gottschalk Adrian See Remarks Director | Foghorn Therapeutics Inc. (FHTX) | 27-Oct-20 | Conversion | 25,225 | -- | -- | 100% 0 to 25.23K | |
| 29-Oct-20 5:01 PM View: | Decicco Carl Chief Scientific Officer | Foghorn Therapeutics Inc. (FHTX) | 27-Oct-20 | Purchase | 5,500 | $16.00 | $88,000.00 | 2% 252.9K to 258.4K | |
| 28-Oct-20 6:02 AM View: | Abu Dhabi Investment Author... | Foghorn Therapeutics Inc. (FHTX) | 27-Oct-20 | Conversion | 1,081,080 | -- | -- | 100% 1.08M to 2.16M | |
| 28-Oct-20 6:02 AM View: | Abu Dhabi Investment Author... | Foghorn Therapeutics Inc. (FHTX) | 27-Oct-20 | Purchase | 150,000 | $16.00 | $2,400,000.00 | 7% 2.16M to 2.31M | |
| 29-Oct-20 4:58 PM View: | Flagship Ventures Fund V Ge... 10% Owner | Foghorn Therapeutics Inc. (FHTX) | 27-Oct-20 | Conversion | 12,524,100 | -- | -- | 100% 0 to 12.52M | |
| 29-Oct-20 4:58 PM View: | Flagship Ventures Fund V Ge... 10% Owner | Foghorn Therapeutics Inc. (FHTX) | 27-Oct-20 | Purchase Duplicate | 150,000 | $16.00 | $2,400,000.00 | 1% 12.52M to 12.67M |
